- Home
- AEMD vs APLM Comparison
AEMD vs APLM Comparison
Compare AEMD & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- APLM
- Stock Information
- Founded
- AEMD 1984
- APLM 2016
- Country
- AEMD United States
- APLM United States
- Employees
- AEMD N/A
- APLM N/A
- Industry
- AEMD Medical/Dental Instruments
- APLM Blank Checks
- Sector
- AEMD Health Care
- APLM Finance
- Exchange
- AEMD Nasdaq
- APLM Nasdaq
- Market Cap
- AEMD 7.3M
- APLM 6.5M
- IPO Year
- AEMD N/A
- APLM N/A
- Fundamental
- Price
- AEMD $0.38
- APLM $6.56
- Analyst Decision
- AEMD Strong Buy
- APLM Strong Buy
- Analyst Count
- AEMD 1
- APLM 1
- Target Price
- AEMD $7.00
- APLM $200.00
- AVG Volume (30 Days)
- AEMD 89.6K
- APLM 58.3K
- Earning Date
- AEMD 02-12-2025
- APLM 04-03-2025
- Dividend Yield
- AEMD N/A
- APLM N/A
- EPS Growth
- AEMD N/A
- APLM N/A
- EPS
- AEMD N/A
- APLM N/A
- Revenue
- AEMD N/A
- APLM $198,000.00
- Revenue This Year
- AEMD N/A
- APLM $415.15
- Revenue Next Year
- AEMD N/A
- APLM N/A
- P/E Ratio
- AEMD N/A
- APLM N/A
- Revenue Growth
- AEMD N/A
- APLM N/A
- 52 Week Low
- AEMD $0.24
- APLM $4.71
- 52 Week High
- AEMD $1.79
- APLM $49.00
- Technical
- Relative Strength Index (RSI)
- AEMD 49.25
- APLM 50.05
- Support Level
- AEMD $0.35
- APLM $5.41
- Resistance Level
- AEMD $0.37
- APLM $6.19
- Average True Range (ATR)
- AEMD 0.03
- APLM 0.76
- MACD
- AEMD 0.01
- APLM 0.10
- Stochastic Oscillator
- AEMD 79.31
- APLM 86.05
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.